Relations between professional medical associations and healthcare industry, concerning scientific communication and continuing medical education: a Policy Statement from the European Society of Cardiology

Choudhry, 2002, Relationships between authors of clinical practice guidelines and the pharmaceutical industry, JAMA, 287, 612, 10.1001/jama.287.5.612 Jibson, 2006, Medical education and the pharmaceutical industry: managing an uneasy alliance, Acad Psychiatry, 30, 36, 10.1176/appi.ap.30.1.36 Moynihan, 2008, Doctors’ education: the invisible influence of drug company sponsorship, BMJ, 336, 416, 10.1136/bmj.39496.430336.DB Podolsky, 2008, A historical perspective of pharmaceutical promotion and physician education, JAMA, 300, 831, 10.1001/jama.300.7.831 Lo B, Field MJ, eds. Conflict of Interest in Medical Research, Education, and Practice. Washington: Institute of Medicine; 2009. ISBN: 978-0-309-13188-9. EFPIA. EFPIA code on the promotion of prescription-only medicines to, and interactions with, healthcare professionals, 2007. www.efpia.eu/Content/Default. asp?PageID=559&DocID=3483.(20 January 2012). FPMA. IFPMA Code of Pharmaceutical Marketing Practices 2006 Revision. Appendix 1. 2006. www.ifpma.org/fileadmin/templates/EthicalPromotion/pdfs/IFPMA-TheCodeOperatingProcedure-2006.pdf. ABPI. Code of practice for the pharmaceutical industry, 2006. www.abpi.org.uk/links/assoc/PMCPA/pmpca_code2006.pdf. Organisation for Economic Co-operation and Development. Recommendation for Further Combating Bribery of Foreign Public Officials in International Business Transactions. Paris, France: OECD; 2009. http://www.oecd.org/document/20/0,3343,en_2649_34859_2017813_1_1_1_1,00.html. (20 January 2012). Hager M, Russell S, Fletcher SW, eds. Continuing education in the health professions: improving healthcare through lifelong learning. Proceedings of a conference sponsored by the Josiah Macy, Jr. Foundation. New York, 2008. ISBN 0-914362-49-6. www.josiahmacyfoundation.org.(20 January 2012). Mazmanian, 2009, Commercial support of continuing medical education in the United States: the politics of doubt, the value of studies, J Contin Educ Health Prof, 29, 81, 10.1002/chp.20015 Chimonas, 2005, New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation, Health Aff (Millwood), 24, 949, 10.1377/hlthaff.24.4.949 Rothman, 2009, Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest, JAMA, 301, 1367, 10.1001/jama.2009.407 Chren, 1994, Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary, JAMA, 271, 684, 10.1001/jama.1994.03510330062035 Wazana, 2000, Physicians and the pharmaceutical industry: is a gift ever just a gift?, JAMA, 283, 373, 10.1001/jama.283.3.373 Hatton, 2008, Pharmacists and industry: guidelines for ethical interactions, Pharmacotherapy, 28, 410, 10.1592/phco.28.3.410 Dickersin, 1990, The existence of publication bias and risk factors for its occurrence, JAMA, 263, 1385, 10.1001/jama.1990.03440100097014 Stelfox, 1998, Conflict of interest in the debate over calcium-channel antagonists, N Engl J Med, 338, 101, 10.1056/NEJM199801083380206 Friedberg, 1999, Evaluation of conflict of interest in economic analyses of new drugs used in oncology, JAMA, 282, 1453, 10.1001/jama.282.15.1453 Ross, 2008, Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation, JAMA, 299, 1800, 10.1001/jama.299.15.1800 Pellegrino, 1999, Professional medical associations: ethical and practical guidelines, JAMA, 282, 984, 10.1001/jama.282.10.984 Ross, 2009, Doctors, patients and the drug industry: partners, friends, or foes?, BMJ, 338, 326 Harrington, 2010, There is a role for industry-sponsored education in cardiology, Circulation, 121, 2221, 10.1161/CIRCULATIONAHA.109.868026 Gelberman, 2010, Orthopaedic surgeons and the medical device industry: the threat to scientific integrity and the public trust, J Bone Joint Surg Am, 92, 765, 10.2106/JBJS.I.01164 Bruyere, 2010, The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES), Osteoporos Int, 21, 713, 10.1007/s00198-010-1190-9 Drazen, 2002, Financial associations of authors, N Engl J Med, 346, 1901, 10.1056/NEJMe020074 Lexchin, 2010, Prohibiting or ‘managing’ conflict of interest?. A review of policies and procedures in three European drug regulation agencies, Soc Sci Med, 70, 643, 10.1016/j.socscimed.2009.09.002 Association of American Medical Colleges. Industry Funding of Medical Education. Report of an AAMC Task Force. Washington, DC: AAMC; 2008. http://services.aamc.org/publications/showfile.cfm?file=version114.pdf. European Commission, SEC(2010) 1161. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Europe 2020 Flagship Initiative. Innovation Union. Brussels, 6.1.2010. http://ec.europa.eu/research/innovation-union/pdf/innovation unioncommunication_en.pdf. Merkur, 2008, Physician revalidation in Europe, Clin Med, 8, 371, 10.7861/clinmedicine.8-4-371 Maisonneuve, 2009, Continuing medical education and professional revalidation in Europe: five case examples, J Contin Educ Health Prof, 29, 58, 10.1002/chp.20007 Fras Z, Destrebecq F, Creplet C, Welling C. Survey of European CME/CPD. Continuing Medical Education and Professional Development. Brussels: European Union of Medicine Specialists (UEMS); 2008. http://www.uems.net/ (20 January 2012). Garattini, 2010, Continuing medical education in six European countries: a comparative analysis, Health Policy, 94, 246, 10.1016/j.healthpol.2009.09.017 Desbois EJ, Pardell H, Negri A, Kellner T, Posel P, Kleinoeder T, Maillet B, Maisonneuve H. Continuing medical education in Europe: evolution or revolution, 2010. http://www .continuingmedicaleducation-europe.com/ (20 January 2012). Organisme Gestionnaire Conventionnel. Rapport d’activité FPC (Formation professionnelle conventionnelle) 2009;10-11. Royal College of Physicians. (RCP). Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, 2009. http://www.rcplondon.ac.uk/pubs/contents/76673804-76c5-4ab3-89a0-92d44e45edc3.pdf. Netherlands Federation of University Medical Centres. Collective agreement for University Medical Centres, 1 January 2008-1 March 2011. NFU-083083, article 15.9.1. http://www.nfu.nl/fileadmin/documents/Werkg-NFU20083083-OFF-ENG-CAOv081016.pdf. Accreditation Council for Continuing Medical Education (ACCME). Annual Report Data 2008. http://www.accme.org/dir_docs/doc_upload/1f8dc476-246a-4e8e-91d3d24ff2f5bfec_uploaddocument.pdf. American Heart Association. AHA annual report 2009. http://www.nxtbook.com/tristar/tristar/aha_annualreport09/index.php#/30 (20 January 2012). Camilleri M, Parke DW 2nd. Perspective: conflict of interest and professional organizations: considerations and recommendations. Acad Med 2010;85: 85-91. Criteria for international accreditation of CME. European Union of Medical Specialists, 2007. http://admin.uems.net/uploadedfiles/1411.pdf. Fletcher S. Pharma and CME: view from the US. BMJ 2008; 337:a1023. Davis, 1995, Changing physician performance: a systematic review of the effect of continuing medical education strategies, JAMA, 274, 700, 10.1001/jama.1995.03530090032018 Davis, 1999, Impact of formal continuing medical education Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes?, JAMA, 282, 867, 10.1001/jama.282.9.867 Bowen Judith, 2006, Medical education: educational strategies to promote clinical diagnostic reasoning, N Engl J Med, 355, 2217, 10.1056/NEJMra054782 Kahn N. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:737. Smith CD, Buyske J, Talamini MA. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:738-739. Coyle, 2002, Part 1: individual physicians, Ann Intern Med, 136, 396, 10.7326/0003-4819-136-5-200203050-00014 Coyle, 2002, Part 2: organizational issues, Ann Intern Med, 136, 403, 10.7326/0003-4819-136-5-200203050-00015 European Medicines Agency (EMA). Policy on the Handling of Conflicts of Interests of Management Board and Scientific Committee Members and EMEA Experts. London: EMA; 2006. http://www.ema.europa.eu/pdfs/general/direct/conflicts/3165303en.pdf. Boyd, 2006, Improving the use of research evidence in guideline development: 4. Managing conflicts of interest, Health Res Policy Syst, 4, 16, 10.1186/1478-4505-4-16 Guyatt, 2010, Schünemann H. The vexing problem of guidelines and conflict of interest: a potential solution, Ann Intern Med, 152, 738, 10.7326/0003-4819-152-11-201006010-00254 Mitchell, 2009, Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry, Med J Aust, 191, 273, 10.5694/j.1326-5377.2009.tb02783.x Schünemann, 2009, ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee An official American Thoracic Society Policy statement: managing conflict of interest in professional societies, Am J Respir Crit Care Med, 180, 564, 10.1164/rccm.200901-0126ST International Committee of Medical Journal Editors. Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest. ICMJE; 2009. http://www. icmje.org/ethical_4conflicts.html (20 January 2012).